Inhibikase Therapeutics, Inc.IKTNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -100.00% | -100.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | -109.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +66.27% | +1021.23% | +1312.10% | +1094.45% | +913.79% |
| Weighted Average Shares Diluted Growth | +66.27% | +1021.23% | +1312.10% | +1094.45% | +913.79% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -75.52% | +579.69% | +751.83% | +906.63% | +1718.52% |
| Book Value per Share Growth | +0.00% | -22.93% | -10.41% | +31.50% | +0.00% |
| Debt Growth | -19.69% | -82.23% | -84.74% | -89.31% | -100.00% |
| R&D Expense Growth | +29.90% | +139.33% | +282.13% | +71.37% | +82.01% |
| SG&A Expenses Growth | +1.32% | +311.41% | +159.29% | +199.78% | +242.67% |